secletter.htm

Stephen J. Cosgrove One Johnson & Johnson Plaza

Vice President New Brunswick, NJ 08933

Corporate Controller (732) 524-3737

June 22, 2009

Mr. Jim B. Rosenberg

Senior Assistant Chief Accountant

Securities and Exchange Commission

Washington, DC 20549

Re: Johnson & Johnson

File No. 001-03215

Dear Mr. Rosenberg:

We have reviewed the comments included in your letter of June 8, 2009 and have prepared the following responses. For your convenience, we have included your comments with this letter. Our response uses the same numbering as your letter.

Comment 1: Please revise your contractual obligations table to include interest expense since it is part of your contractual obligation of debt.

Response 1: Below is what the contractual obligations and commitments table, revised to include interest expense, would have looked like in the Company’s Annual Report for the fiscal year ended December 28, 2008. The Company intends to include this table in its Annual Report for the 2009 fiscal year using the same presentation as shown below.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

The Company has contractual obligations, primarily lease, debt obligations and related interest and unfunded retirement plans, with no other significant obligations. To satisfy these obligations, the Company will use cash from operations. The following table summarizes the Company’s contractual obligations and their aggregate maturities as of December 28, 2008 (see Notes 4, 6 and 13 to the Consolidated Financial Statements for further details):

(Dollars in Millions)

					Interest on		Unfunded
	Operating		Debt		Debt		Retirement
	Leases		Obligations		Obligations		Plans		Total

2009	$	171		221		475		56		923
2010		145		22		456		58		681
2011		123		18		453		62		656
2012		107		620		440		66		1,233
2013		89		507		410		70		1,076
After 2013		93		6,953		4,927		436		12,409
Total	$	728		8,341		7,161		748		16,978

-2-

Comment 2: Refer to your disclosure “sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall.” Revise your disclosure to address:

·	Whether you refund the sales price by issuing cash or a credit, or whether you exchange product from your inventory for the returned product;

·	Whether the returned product is resalable; and

If you exchange product from your inventory for the returned product, how you account for your estimate of returns at the time of the product sale and how you account for returns when they are actually returned and make the exchange. Provide us an analysis supporting your accounting treatment with reference to authoritative literature. It also may be helpful to provide us an example showing the journal entries made.

Response 2: In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales return reserves are accounted for in accordance with FASB Statement No. 48 “Revenue Recognition When Right of Return Exists.” Sales return reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. While sales returns in the Medical Devices & Diagnostics segment are generally not resalable, certain franchises in this segment may receive returned product that is resalable, however such amounts have not been significant in the past. The Company rarely exchanges products from inventory for returned products. Sales return reserves are based on historical return trends by product. The sales returns reserve for the total Company has ranged between 1.1% and 1.2% of annual net trade sales during the prior three fiscal reporting years 2006-2008.

The Company will expand its disclosures in its annual report for the 2009 fiscal year to include response 2 above.

The Company acknowledges that it is responsible for the adequacy and accuracy of all disclosures in its filings. The Company understands that SEC staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filings and the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States of America.

If you have any questions or comments, please call me at (732) 524-3737 or Phil Savas, Assistant Corporate Controller at (732) 524-3566.

Sincerely,



		/s/
		Stephen J. Cosgrove
		Vice President, Controller (Principle Accounting Officer)